In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INTERVIEW: Natco's CEO, India's price warrior

This article was originally published in Scrip

Executive Summary

Natco Pharmaceuticals' CEO Rajeev Nannapaneni says that unless multinational companies consider pricing based on factors such as GDP and purchasing power parity, the debate on pricing and access may spin out of control – and then market intervention would follow.

You may also be interested in...



Novartis Logs Into India With Digital Innovation Hub

Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.

Seretide Settlement To Lift Glenmark’s Europe Business

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.

India Regulatory Diary: Marketers Co-Accountable For Lapses In Manufacturing Quality

New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.

Topics

Related Companies

UsernamePublicRestriction

Register

SC019380

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel